Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers

Figures

• 

  Figure 1. A graphical representation summarizing the topics that will be analyzed in this review article. Specifically, we will start by listing methodologies in which drug repurposing can be achieved (computationally and experimentally). Then, we will examine how drugs that act as AT1 receptor inhibitors can also exert their effects in other pathologies. Specifically, we will start with the ‘core’ diseases that often coexist in patients taking these drugs (HT; hypertension, HF; heart failure, CKD; chronic kidney disease, ACS; acute coronary syndrome). Then, we will list the diseases in which the RAAS plays an important role and therefore inhibition of AT1 receptors could help in the treatment of patients as indicated in research (AD; Alzheimer’s disease, PD; Parkinson’s disease, RA; rheumatoid arthritis, OA; osteoarthritis, DN; diabetic nephropathy, DPN; diabetic peripheral neuropathy, SARS-CoV-2, CS; candidosis, FS; fibrosis, TFSSc; tissue fibrosis in systemic sclerosis, GC; glioma cancer, MS; Marfan syndrome, IBDs; inflammatory bowel diseases, AT; anxiety, PI; pathogenic inflammation, OPA; opioid addiction). Finally, we highlight the work of our laboratory and collaborators towards the…

• 

  Figure 2. A schematic representation of the compounds designed, synthesized, and studied in silico, in vitro, and in vivo by our laboratory and collaborators over the years. All of them can be separated into 4 major groups: (1) molecules discovered and designed with the contribution of databases, (2) molecules that are sartan derivatives, (3) hybrid molecules, and (4) molecules with a simple structure that satisfactorily inhibit AT1 receptors.